← Retour au Screener

Sector: Santé
Open in Terminal → CTKBLive chart · Key metrics · News · Smart money

Cytek Biosciences, Inc.

CTKB Small Cap

Healthcare · Medical Devices

Mis à jour: Jun 18, 2026, 22:21 UTC

3,29 €
-5.28% aujourd'hui
52W: 2,53 € – 5,39 €
52W Low: 2,53 € Position: 26.5% 52W High: 5,39 €

Price Chart

Indicateurs clés

P/E Ratio
Cours/Bénéfice
Forward P/E
19.84x
P/E prévisionnel
P/S Ratio
2.38x
Cours/Ventes
EV/EBITDA
Valeur d'entreprise/EBITDA
Rend. dividende
Rendement annuel du dividende
Cap. boursière
424 M €
Capitalisation boursière
Croissance du CA
6.5%
Croissance du CA sur un an
Marge bénéficiaire
-36.25%
Marge nette
ROE
-20.93%
Rentabilité des capitaux propres
Beta
1.19
Sensibilité au marché
Positions vendeuses
7.17%
% du flottant vendu à découvert
Volume moyen
919,580
Volume quotidien moyen

Valuation Analysis

Signal
N/A
vs. S&P 500 avg P/E (24.7x)
Analyst Consensus
None
4 analysts
Avg. Price Target
4,96 €
+50.86% upside
Target Range
4,14 € – 6,54 €

About the Company

Sector: Healthcare Industry: Medical Devices Country: United States Employees: 678 Exchange: NMS

Cytek Biosciences, Inc. en bref

Cytek Biosciences, Inc. (CTKB) is currently trading at 3,29 € with a market capitalization of 424 M €. The 52-week range spans from 2,53 € to 5,39 €; the current price is 39% below the yearly high. Year-over-year revenue growth stands at +6.5%.

💰 Dividende

Cytek Biosciences, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

4 analystes évaluent Cytek Biosciences, Inc. (CTKB) au consensus : None. L'objectif de cours moyen est de 4,96 €, soit un potentiel de +50.86% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 4,14 € à 6,54 €.

Cytek Biosciences, Inc. : la thèse d'investissement en détail

Cytek Biosciences, Inc. (CTKB) operates in the Healthcare — specifically Medical Devices — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario baissier

Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders.

À surveiller

  • The analyst consensus price target implies 50.86% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Points forts
  • Marge brute élevée de 51.7% — signe d'un pouvoir de fixation des prix
  • Bilan solide avec faible endettement (D/E 8.39)
  • Free cash flow positif
Points faibles
  • Actuellement non rentable

Aperçu technique

MM 50 jours
3,71 €
-11.5% vs. cours
MM 200 jours
3,91 €
-15.85% vs. cours
Sous le plus haut 52s
−39%
5,39 €
Au-dessus du plus bas 52s
+30%
2,53 €

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Profil de risque

Risque de marché (Bêta)
1.19 · Proche du marché
Évolue plus que le marché global
Positions vendeuses
7.17% · Élevé
% du flottant vendu à découvert
Dette/Capitaux propres
8.39 · Faible
Dette totale / capitaux propres

The data points to market-like volatility, elevated short interest (7.17%).

Trading Data

50-Day MA: 3,71 €
200-Day MA: 3,91 €
Volume: 15,687,850
Avg. Volume: 919,580
Short Ratio: 7.05
P/B Ratio: 1.49x
Debt/Equity: 8.39x
Free Cash Flow: 6 M €

More Santé stocks

Top peers in the same sector — ranked by market cap.

View full Santé sector page →

Where can I buy Cytek Biosciences, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.

Live Market Data

Real-time chart, financials, earnings, analysts, insider trades, events & news

Financials

Earnings

Analyst Ratings

Insider Trades

Events Timeline

News + Sentiment

Peer Comparison

Retour en haut